Advertisement

Topics

Bronchiectasis - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Bronchiectasis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 74-page report is available in PDF from $2000.

Bronchiectasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bronchiectasis - Pipeline Review, H1 2015’, provides an overview of the Bronchiectasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchiectasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bronchiectasis Overview 7
Therapeutics Development 8
Pipeline Products for Bronchiectasis - Overview 8
Pipeline Products for Bronchiectasis - Comparative Analysis 9
Bronchiectasis - Therapeutics under Development by Companies 10
Bronchiectasis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bronchiectasis - Products under Development by Companies 14
Bronchiectasis - Companies Involved in Therapeutics Development 15
Alitair Pharmaceuticals, Inc. 15
Bayer AG 16
Clarassance, Inc. 17
GlaxoSmithKline plc 18
Grifols, S.A. 19
Kamada Ltd. 20
Nostrum Pharmaceuticals, LLC 21
Pulmatrix, Inc. 22
Recipharm AB 23
Savara Inc. 24
Serendex Pharmaceuticals A/S 25
Bronchiectasis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
alpha-1 proteinase inhibitor (human) second generation - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ALT-07 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ALT-09 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ARD-3150 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BAY-858501 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CG-1011 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ciprofloxacin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
dapsone - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
erdosteine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GSK-2793660 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Leukotriene B4 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
levofloxacin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
molgramostim - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Human Follistatin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
vancomycin hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Bronchiectasis - Recent Pipeline Updates 58
Bronchiectasis - Dormant Projects 64
Bronchiectasis …

For more information open Bronchiectasis - Pipeline Review, H1 2015.

SKU: GMDHC6611IDB

Original Article: Bronchiectasis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Bronchiectasis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...